Methods for ablating myeloid derived suppressor cells using neo-201 antibody

A method of therapy, which comprises the administration of an antibody or antibody fragment which binds to glycosylated CEACAM 5 and CEACAM6 carrying core-1 and/or extended core-1 O-glycans but not to aglycosylated CEACAM 5 or aglycosylated CEACAM6;

• optionally NEO-201 or an antigen binding fragment thereof, which method results in one or more of the following:
• (i) killing or ablating granulocyte derived myeloid derived suppressor cells (gMDSCs) in a patient in need thereof;
• (ii) reversing tolerance and/or restoring innate immunity, e.g., innate antitumor immunity or innate anti-infectious immunity in a patient in need thereof by killing or ablating granulocyte myeloid derived suppressor cells (gMDSCs) in the patient;
• (iii) reversing resistance or tolerance to an anti-cancer or anti-infectious agent treatment, e.g., an immune modulatory antibody, a checkpoint inhibitor antibody or fusion protein, or a chemotherapeutic agent, which resistance or tolerance involves granulocyte myeloid derived suppressor cells;
• or
• (iv) treating or preventing cancer or infection reoccurrence by suppressing the proliferation of gMDSCs, thereby reestablishing innate immunity.